Vycor Medical

What Vycor Medical does

Vycor Medical, Inc. is a publicly traded medical device company (OTCQB: VYCO) headquartered in Boca Raton, Florida, operating two distinct business units: Vycor Medical, which markets the ViewSite Brain Access System (VBAS), an FDA 510(k)-cleared disposable tubular retractor made of polished transparent polycarbonate used for minimally invasive neurosurgical access to brain and spinal lesions; and NovaVision, Inc., a wholly-owned subsidiary that delivers non-invasive, computer-based vision rehabilitation therapies (Visual Restoration Therapy and NeuroEyeCoach) for patients with vision loss resulting from stroke or other neurological brain injury.

The VBAS system consists of clear cylindrical retractors in 12 sizes ranging from 6mm to 28mm in width and 3cm to 7cm in length, with an elliptical cross-section that disperses retraction pressure and a blunt tip that splits rather than transects white matter. Enhanced VBAS variants integrate with common neuronavigation platforms via an internal pointer cup and an optional Alignment Clip (VBAS AC), and an FDA Class I 510(k)-exempt Extension Arm accessory supports fixation-system compatibility. NovaVision's VRT is positioned as the only FDA-cleared therapy for vision restoration following neurological brain damage, while NeuroEyeCoach is a compensation therapy whose evidence base includes a 296-patient peer-reviewed study.

Vycor generates approximately 96% of revenue from VBAS hardware sales and approximately 4% from NovaVision (which remains a development-stage business with nine-month 2025 revenue of approximately $54,000). Vycor Medical sells VBAS in the United States through a network of over 100 independent neuro-surgical sales representatives targeting more than 350 hospitals, and internationally through regional distributors across the US, Canada, the UK, the EU, Japan, China, Korea, Australia, and Brazil, with new 2025 distribution agreements for France and Spain. NovaVision historically operated a German office, which was closed in 2020 in favor of an exclusive DACH-region licensing arrangement with HelferApp GmbH. FY2024 revenue was $1,589,324 with gross margins of approximately 84-90%, and nine-month 2025 revenue was $1,446,523, up 28% year-on-year. Management has engaged Maxim Group LLC to advise on corporate strategy, including a potential uplisting to a US national exchange.

Name

Vycor Medical

Legal name

Vycor Medical, Inc.

Website

https://vycormedical.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Short description

Vycor Medical is a public medical device company that markets the ViewSite Brain Access System, an FDA-cleared minimally invasive neurosurgical retractor sold to hospitals, and NovaVision, FDA-cleared computer-based vision rehabilitation therapies for stroke and brain-injury patients.

Ownership category

akta.pro rank

Product category

Neurosurgical Medical Devices

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Neuro-Ophthalmology (HLAKAKAH)

akta.pro secondary industry

Vision Therapy & Orthoptics (HLAKAKAM)

Keywords

• Neurosurgical medical devices
• Minimally invasive brain surgery
• Vision rehabilitation therapy
• Tubular retractor systems
• Neurological therapy solutions

Headquarters

HQ city

Boca Raton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. VBAS Medical Device Sales: Vycor Medical generates revenue primarily from sales of its ViewSite Brain Access System (VBAS), a disposable minimally invasive neurosurgical device. Revenue is approximately 96% from Vycor Medical division and 4% from NovaVision division. VBAS is sold to hospitals for use in neurosurgical procedures including tumor removal, intracerebral hemorrhage evacuation, and other brain surgeries.
2. NovaVision Vision Therapy Programs: NovaVision division generates revenue from its suite of vision rehabilitation therapies including Visual Restoration Therapy (VRT) and NeuroEyeCoach for patients suffering from vision loss due to stroke or brain injury. NovaVision remains a business in development with revenues of approximately $54,000 for nine months ended September 30, 2025.
3. NovaVision Licensing Agreements: NovaVision licenses its diagnostic products and therapies to regional partners. In June 2020, NovaVision entered into an exclusive licensing agreement with HelferApp GmbH for Germany, Austria and Switzerland, granting rights for NovaVision's products direct to patients and medical professionals.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

Vycor Medical operates two business units. The Vycor Medical division designs, manufactures, and markets the ViewSite Brain Access System (VBAS), a clear cylindrical disposable tubular retractor used by neurosurgeons for minimally invasive access to brain lesions including tumors and intracerebral hemorrhages. The NovaVision division provides non-invasive, computer-based vision rehabilitation therapies—Visual Restoration Therapy (VRT) and NeuroEyeCoach—for patients suffering vision loss resulting from stroke or other neurological trauma.

Product overview

Vycor Medical operates two distinct business units offering a portfolio of medical devices and therapies. Vycor Medical division markets the ViewSite™ Brain Access System (VBAS™), a suite of clear cylindrical disposable devices for minimally invasive neurosurgery access to brain lesions, available in various sizes with an optional Alignment Clip (VBAS AC) for neuronavigation integration and an Extension Arm accessory. NovaVision division provides non-invasive computer-based vision rehabilitation therapies including Visual Restoration Therapy (VRT) — the only FDA-cleared therapy for vision rehabilitation following neurological brain damage — and NeuroEyeCoach®, a compensation therapy for visual field deficit training.

Differentiator

Problem solved

Functional benefit

Brands

• ViewSite Brain Access System (VBAS): FDA-cleared minimally invasive neurosurgical device for accessing brain lesions. Clear cylindrical disposable retractor system used to access tumors, intracerebral hemorrhages, and other target sites within the brain.
• NovaVision
• NovaVision VRT (Visual Restoration Therapy)
• NeuroEyeCoach

Products and services

• ViewSite Brain Access System (VBAS) A minimally invasive FDA 510(k)-cleared neurosurgical device consisting of clear cylindrical disposable tubular retractors used to access target sites such as tumors and intracerebral hemorrhages within the brain. VBAS provides both retraction and a stable working channel during neurosurgery. Available in sizes ranging from 6mm to 28mm width and 3cm to 7cm length, with transparent polycarbonate construction and compatibility with most commonly used neuronavigation platforms.
• Visual Restoration Therapy (VRT) The only commercially available FDA-cleared therapy designed to restore vision loss due to neurological brain damage from stroke or other brain injury. It works by strengthening the brain's ability to process visual information through repeated exercises. Targeted at patients with vision disorders resulting from stroke or brain trauma.
• NeuroEyeCoach A computer-based compensation visual therapy designed to help patients compensate for visual field deficits by training their eyes to quickly scan their environment, making it easier to find and focus on objects. FDA-registered. Supported by a 296-patient peer-reviewed study showing 87% improvement in search time and 80% of patients making fewer errors. For patients with vision loss from stroke or brain injury.
• VBAS AC (Alignment Clip) An enhanced version of VBAS featuring an alignment clip that clamps onto the proximal end of the introducer, allowing neuronavigation pointers to be firmly held in place during surgery for single-handed use. Available for 5cm and 7cm length models. Designed for use with commonly used Image Guidance System pointers.
• Extension Arm A reusable accessory designed as an extension between a tubular retractor and commonly used Fixation Systems. Minimizes obstruction and visual interference while maximizing stabilization and fixation of a tubular retractor. FDA Class I 510(k) exempt device.

Quantifiable outcome

• Less brain tissue damage demonstrated in 50+ peer-reviewed clinical studies
• +5 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered minor and core.

• France and Spain DistributorsminorChannel Partner/ Reseller/ Distributor · 1 January 2025New distribution agreements entered for France and Spain during the six months ended June 30, 2025 as part of international expansion strategy targeting these important European markets.
• University of Verona (Neurorehabilitation unit of Neuromotor and Cognitive Rehabilitation Research Centre)minorStrategic or Co-development Partner · 1 January 2025Collaboration with University of Verona for clinical study comparing home-based and clinic-based use of NeuroEyeCoach. Study published in Springer May 2025 Experimental Brain Research, validating NeuroEyeCoach effectiveness in both settings.
• HelferApp GmbHcoreOEM/ Whitelabel/ Licensing Partner · 30 June 2020Exclusive licensing agreement granting HelferApp rights for NovaVision's diagnostic products and therapies direct to patients and medical professionals in Germany, Austria, and Switzerland. The combination allows HelferApp to create an unrivalled portfolio of scientifically supported therapies addressing the visual rehabilitation market in the territories. Existing NovaVision patients in covered regions transferred to HelferApp.
• University of Aberdeen / University of Miami Miller School of MedicinecoreStrategic or Co-development Partner · 1 February 2020Clinical research collaboration led by Professor Arash Sahraie from University of Aberdeen and Dr. Jose Romano from University of Miami Miller School of Medicine. Produced landmark 296-patient study on NeuroEyeCoach published in Cortex journal, demonstrating effectiveness of vision rehabilitation therapy.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Penumbra, Inc. Penumbra develops neurovascular and neurosurgery devices including aspiration and access systems for stroke and brain surgery, directly competing with Vycor in the minimally invasive neurosurgery procedural space and serving the same hospital neurology/neurosurgery departments.
• Stryker Corporation: Stryker acquired Nico Corporation (developer of the BrainPath tubular retractor) in 2020, making it the most direct competitor to Vycor's VBAS in minimally invasive neurosurgical access. Stryker's broad neurosurgery portfolio and global hospital relationships create a formidable incumbent against Vycor's specialized offering.

Broad incumbents

• Carl Zeiss Meditec AG: ZEISS Meditec is a global leader in surgical microscopes and ophthalmic devices. While its core focus is ophthalmology and microsurgery visualization, its products are used in the same neurosurgical operating rooms where VBAS is deployed, making it a complementary incumbent in the neurosurgery OR.
• Integra LifeSciences Holdings Corporation: Integra is a major neurosurgical products company offering a broad portfolio of dural repair, retraction, and access devices. It serves as a dominant incumbent in many neurosurgery adjacencies where Vycor's VBAS competes, with established hospital relationships globally.
• Medtronic plc: Medtronic's Cranial & Spinal Technologies division offers a wide range of neurosurgical instruments, StealthStation navigation systems, and disposables, broadly overlapping with Vycor's hospital customer base and surgical workflows while offering far greater scale and resources.

Others

• Brainlab AG: Brainlab is a leading surgical navigation and planning software company whose neuronavigation platforms (Curve, Kick, Buzz) integrate with VBAS. As a complementary technology provider, Brainlab is both an indirect competitor in neurosurgery OR equipment and an ecosystem partner through VBAS's neuronavigation compatibility.

Emerging players

• Synaptive Medical Inc. Synaptive Medical develops neurosurgical visualization, access, and AI-assisted planning tools (Modus V, BrightMatter) that overlap with Vycor's minimally invasive neurosurgery positioning, particularly in deep brain tumor access and tractography-guided procedures.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/vycormedical
• YouTubeyoutube.com/@vycormedical6049
• Facebookfacebook.com/vycor
• LinkedInlinkedin.com/company/vycormedical
• Instagraminstagram.com/vycormedical

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vycor Medical